Niox Group (NIOX.L) Stock Price

Niox Group Price

LSE·CLOSED
0.69GBP-0.0020 (-0.29 %)
Market closed

Revenue has compounded at 16.2% per year over the past 9 years to 41.80 M GBP. Earnings per share have declined at 0.0% per year over the last 3 years. Niox Group's net margin stands at 8.9%, up from -140.2% several years earlier. Niox Group currently offers a dividend yield of about 1.46%. The payout ratio is around 132% of earnings. Analysts set a median price target of 83.64 GBP, implying 12,092.4% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 26% above its 52-week low.

Niox Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Niox Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Niox Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Niox Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Niox Group Stock Price History
DateNiox Group Price
8/21/20260.69 GBP
8/20/20260.69 GBP
8/19/20260.68 GBP
8/18/20260.68 GBP
8/17/20260.67 GBP
8/14/20260.68 GBP
8/13/20260.66 GBP
8/12/20260.65 GBP
8/11/20260.65 GBP
8/10/20260.63 GBP
8/7/20260.62 GBP
8/6/20260.63 GBP
8/5/20260.62 GBP
8/4/20260.61 GBP
7/31/20260.60 GBP
7/30/20260.62 GBP
7/29/20260.61 GBP
7/28/20260.63 GBP
7/27/20260.65 GBP
7/24/20260.64 GBP
7/23/20260.62 GBP
7/22/20260.62 GBP
7/21/20260.61 GBP
7/20/20260.59 GBP
7/17/20260.59 GBP
7/16/20260.59 GBP
7/15/20260.59 GBP
7/14/20260.59 GBP
7/13/20260.57 GBP
7/10/20260.58 GBP
7/9/20260.57 GBP
7/8/20260.58 GBP
7/7/20260.59 GBP
7/6/20260.59 GBP
7/3/20260.59 GBP
7/2/20260.59 GBP
7/1/20260.59 GBP
6/30/20260.60 GBP
6/29/20260.56 GBP
6/26/20260.57 GBP
6/25/20260.55 GBP
6/24/20260.58 GBP
6/23/20260.58 GBP
6/22/20260.57 GBP
6/19/20260.56 GBP
6/18/20260.57 GBP
6/17/20260.58 GBP
6/16/20260.57 GBP
6/15/20260.58 GBP
6/12/20260.58 GBP
6/11/20260.57 GBP
6/10/20260.59 GBP
6/9/20260.61 GBP
6/8/20260.60 GBP
6/5/20260.60 GBP
6/4/20260.61 GBP
6/3/20260.61 GBP
6/2/20260.59 GBP
6/1/20260.58 GBP
5/29/20260.57 GBP
5/28/20260.58 GBP
5/27/20260.59 GBP
5/26/20260.59 GBP
5/22/20260.59 GBP
5/21/20260.60 GBP
5/20/20260.62 GBP
5/19/20260.61 GBP
5/18/20260.60 GBP
5/15/20260.61 GBP
5/14/20260.62 GBP
5/13/20260.63 GBP
5/12/20260.63 GBP
5/11/20260.62 GBP
5/8/20260.62 GBP
5/7/20260.64 GBP
5/6/20260.66 GBP
5/5/20260.66 GBP
5/1/20260.67 GBP
4/30/20260.68 GBP
4/29/20260.70 GBP
4/28/20260.68 GBP
4/27/20260.68 GBP
4/24/20260.66 GBP
4/23/20260.65 GBP
4/22/20260.59 GBP
4/21/20260.59 GBP
4/20/20260.58 GBP
4/17/20260.57 GBP
4/16/20260.57 GBP
4/15/20260.56 GBP
4/14/20260.57 GBP
4/13/20260.57 GBP
4/10/20260.58 GBP
4/9/20260.56 GBP
4/8/20260.57 GBP
4/7/20260.57 GBP
4/2/20260.55 GBP
4/1/20260.59 GBP
3/31/20260.59 GBP
3/30/20260.58 GBP
3/27/20260.58 GBP
3/26/20260.58 GBP
3/25/20260.58 GBP
3/24/20260.57 GBP
3/23/20260.55 GBP
3/20/20260.56 GBP
3/19/20260.58 GBP
3/18/20260.58 GBP
3/17/20260.59 GBP
3/16/20260.62 GBP
3/13/20260.62 GBP
3/12/20260.61 GBP
3/11/20260.63 GBP
3/10/20260.63 GBP
3/9/20260.62 GBP
3/6/20260.63 GBP
3/5/20260.64 GBP
2/26/20260.63 GBP
2/25/20260.63 GBP
2/24/20260.63 GBP
2/23/20260.63 GBP
2/20/20260.63 GBP
2/19/20260.63 GBP
2/18/20260.65 GBP
2/17/20260.64 GBP
2/16/20260.65 GBP
2/13/20260.63 GBP
2/12/20260.65 GBP
2/11/20260.65 GBP
2/10/20260.68 GBP
2/9/20260.67 GBP
2/6/20260.66 GBP
2/5/20260.66 GBP
2/4/20260.66 GBP
2/3/20260.66 GBP
2/2/20260.66 GBP
1/30/20260.67 GBP
1/29/20260.68 GBP
1/28/20260.67 GBP
1/27/20260.68 GBP
1/26/20260.70 GBP
1/23/20260.69 GBP
1/22/20260.67 GBP
1/21/20260.66 GBP
1/20/20260.66 GBP
1/19/20260.69 GBP
1/16/20260.69 GBP
1/15/20260.70 GBP
1/14/20260.69 GBP
1/13/20260.68 GBP
1/12/20260.68 GBP
1/9/20260.69 GBP
1/8/20260.67 GBP
1/7/20260.66 GBP
1/6/20260.66 GBP
1/5/20260.66 GBP
1/2/20260.68 GBP
12/31/20250.66 GBP
12/30/20250.67 GBP
12/29/20250.66 GBP
12/24/20250.68 GBP
12/23/20250.66 GBP
12/22/20250.66 GBP
12/19/20250.67 GBP
12/18/20250.69 GBP
12/17/20250.69 GBP
12/16/20250.68 GBP
12/15/20250.68 GBP
12/12/20250.68 GBP
12/11/20250.67 GBP
12/10/20250.69 GBP
12/9/20250.69 GBP
12/8/20250.71 GBP
12/5/20250.70 GBP
12/4/20250.71 GBP
12/3/20250.71 GBP
12/2/20250.71 GBP
12/1/20250.71 GBP
11/28/20250.71 GBP
11/27/20250.72 GBP
11/26/20250.72 GBP
11/25/20250.71 GBP
11/24/20250.72 GBP
11/21/20250.71 GBP
11/20/20250.72 GBP
11/19/20250.71 GBP
11/18/20250.70 GBP
11/17/20250.71 GBP
11/14/20250.70 GBP
11/13/20250.70 GBP
11/12/20250.71 GBP
11/11/20250.71 GBP
11/10/20250.68 GBP
11/7/20250.67 GBP
11/6/20250.65 GBP
11/5/20250.67 GBP
11/4/20250.67 GBP
11/3/20250.68 GBP
10/31/20250.69 GBP
10/30/20250.69 GBP
10/29/20250.69 GBP
10/28/20250.70 GBP
10/27/20250.70 GBP
10/24/20250.70 GBP
10/23/20250.70 GBP
10/22/20250.70 GBP
10/21/20250.70 GBP
10/20/20250.72 GBP
10/17/20250.72 GBP
10/16/20250.73 GBP
10/15/20250.73 GBP
10/14/20250.75 GBP
10/13/20250.76 GBP
10/10/20250.75 GBP
10/9/20250.74 GBP
10/8/20250.74 GBP
10/7/20250.74 GBP
10/6/20250.75 GBP
10/3/20250.75 GBP
10/2/20250.74 GBP
10/1/20250.74 GBP
9/30/20250.73 GBP
9/29/20250.73 GBP
9/26/20250.73 GBP
9/25/20250.73 GBP
9/24/20250.73 GBP
9/23/20250.73 GBP
9/22/20250.74 GBP
9/19/20250.74 GBP
9/18/20250.73 GBP
9/17/20250.72 GBP
9/16/20250.71 GBP
9/15/20250.70 GBP
9/12/20250.70 GBP
9/11/20250.70 GBP
9/10/20250.71 GBP
9/9/20250.72 GBP
9/8/20250.73 GBP
9/5/20250.74 GBP
9/4/20250.74 GBP
9/3/20250.73 GBP
9/2/20250.74 GBP
9/1/20250.74 GBP
8/29/20250.76 GBP
8/28/20250.74 GBP
8/27/20250.72 GBP
8/26/20250.70 GBP
Access this data via the Eulerpool API
Get Free API Key

Niox Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
31.30 M GBP
1.80 M GBP
16.10 M GBP
Jan 1, 2023
36.80 M GBP
4.60 M GBP
10.70 M GBP
Jan 1, 2024
41.80 M GBP
7.70 M GBP
3.70 M GBP
Jan 1, 2025 (e)
48.70 M GBP
7.79 M GBP
10.63 M GBP
Jan 1, 2026 (e)
50.50 M GBP
8.07 M GBP
14.87 M GBP
Jan 1, 2027 (e)
54.79 M GBP
8.76 M GBP
16.68 M GBP
Jan 1, 2028 (e)
58.16 M GBP
9.30 M GBP
17.42 M GBP
Jan 1, 2029 (e)
76.82 M GBP
22.85 M GBP
0.00 GBP

Niox Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 23, 2026, 11:22 PM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
DIV.GBP
DIV. GROWTH%
SHARESM
201420152016201720182019202020212022202320242025e2026e2027e2028e2029e
–10.0023.0046.0048.0034.0023.0027.0031.0036.0041.0048.0050.0054.0058.0076.00
––130.00100.004.35-29.17-32.3517.3914.8116.1313.8917.074.178.007.4131.03
–70.0065.2280.4381.2573.5369.5770.3770.9772.2273.1773.1773.1773.1773.1773.17
30.007.0015.0037.0039.0025.0016.0019.0022.0026.0030.0035.1236.5939.5142.4455.61
-45.00-67.00-43.00-36.00-36.00-18.00-16.00-4.001.004.007.007.008.008.009.0022.00
–-670.00-186.96-78.26-75.00-52.94-69.57-14.813.2311.1117.0714.5816.0014.8115.5228.95
-35.00-49.00-137.00-99.00-117.00-48.00-33.003.0016.0010.003.0010.0014.0016.0017.00–
84.2140.00179.59-27.7418.18-58.97-31.25-109.09433.33-37.50-70.00233.3340.0014.296.25–
––––––––––0.010.010.020.02––
–––––––––––––100.00––
169.12249.58284.89319.54344.35373.70381.86435.83443.00449.28448.21448.21448.21448.21448.21448.21
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Niox Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Niox Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Niox Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Niox Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Niox Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Niox Group stock margins

The Niox Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Niox Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Niox Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
68.20 %
-68.20 %
-140.17 %
Jan 1, 2021
68.10 %
-15.41 %
12.90 %
Jan 1, 2022
70.93 %
5.75 %
51.44 %
Jan 1, 2023
72.01 %
12.50 %
29.08 %
Jan 1, 2024
72.25 %
18.42 %
8.85 %
Jan 1, 2025 (e)
72.25 %
15.99 %
21.83 %
Jan 1, 2026 (e)
72.25 %
15.99 %
29.45 %
Jan 1, 2027 (e)
72.25 %
15.99 %
30.45 %

Niox Group Stock Revenue, EBIT, Earnings per Share

The Niox Group earnings per share therefore indicates how much revenue Niox Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.06 GBP
-0.04 GBP
-0.09 GBP
Jan 1, 2021
0.06 GBP
-0.01 GBP
0.01 GBP
Jan 1, 2022
0.07 GBP
0.00 GBP
0.04 GBP
Jan 1, 2023
0.08 GBP
0.01 GBP
0.02 GBP
Jan 1, 2024
0.09 GBP
0.02 GBP
0.01 GBP
Jan 1, 2025 (e)
0.12 GBP
0.02 GBP
0.03 GBP
Jan 1, 2026 (e)
0.12 GBP
0.02 GBP
0.04 GBP
Jan 1, 2027 (e)
0.13 GBP
0.02 GBP
0.04 GBP

Niox Group business model & stock analysis

Circassia Group plc is a British biotechnology company specializing in the development of therapies for respiratory diseases. The company was founded in 2006 and is headquartered in Oxford. Circassia was founded by Steve Harris, who previously worked for the biopharmaceutical company Xenova Group plc. In its early years, the company focused on research and development of therapies for allergies and asthma. In 2014, Circassia went public on the London Stock Exchange. The company has developed an innovative business model that focuses on using its proprietary technology platform to identify novel therapy candidates. It works closely with pharmaceutical companies and other partners to accelerate the development of its therapy products and license its technology platform. Circassia's main focus is on developing therapies for respiratory diseases, particularly allergic asthma and chronic obstructive pulmonary disease (COPD). It has a range of products currently in various stages of clinical development. One of its leading products is NIOX VERO, a diagnostic device used to measure inflammation in the airways and improve the diagnosis of patients with asthma or COPD. Circassia also has a promising pipeline of therapy candidates, including Flutiform® (fluticasone propionate/formoterol fumarate), an inhaled medication for the treatment of asthma developed in collaboration with Japanese pharmaceutical company Kyorin. Additionally, the company has developed two novel drugs in the field of allergic rhinoconjunctivitis, one of which is currently being tested in phase III studies, while the other is nearing completion of phase II development. In conclusion, Circassia has established itself as an innovative biotechnology company focused on the development of therapies for respiratory diseases. It has a promising pipeline of therapy candidates at various stages of clinical development. The Circassia business model is based on utilizing its proprietary technology platform to identify and develop novel therapy candidates.

Niox Group SWOT Analysis

Strengths

Circassia Group PLC has a strong portfolio of innovative products in the respiratory and autoimmune disease markets, allowing them to effectively address unmet medical needs.

The company has a highly skilled and experienced management team, with a track record of successfully developing and commercializing pharmaceutical products.

Circassia has established strategic partnerships with leading pharmaceutical companies, which provides access to additional resources, expertise, and markets.

Weaknesses

Circassia Group PLC heavily relies on a limited number of products for its revenue, making it vulnerable to any setbacks or regulatory issues in these products.

The company operates in a highly competitive market, with potential challenges in pricing, marketing, and gaining market share against larger pharmaceutical companies.

Circassia has a relatively small market presence compared to its competitors, which may limit its ability to negotiate favorable terms with suppliers or distribution partners.

Opportunities

The increasing prevalence of respiratory and autoimmune diseases offers a significant growth opportunity for Circassia Group PLC, as there is an expanding patient population in need of effective treatments.

Expanding into new geographic markets, particularly emerging markets with underpenetrated healthcare systems, could provide additional revenue streams and diversify the company's customer base.

Advancements in technology and research present opportunities for Circassia to develop and commercialize innovative therapeutics, giving them a competitive edge in the market.

Threats

The regulatory environment for pharmaceutical companies is complex and subject to change, posing a potential threat to Circassia's product development, approval, and commercialization processes.

Competitors in the respiratory and autoimmune disease markets are continually launching new products and therapies, creating a competitive threat to Circassia's market share.

Changes in healthcare policies and reimbursement systems, such as pricing pressures and insurance coverage, could impact the demand and pricing of Circassia's products.

Niox Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Niox Group historical P/E ratio, EBIT multiple, and P/S ratio

Niox Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Niox Group shares outstanding

The number of shares of Niox Group was 448.21 M in 2025. This indicates how many shares Niox Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
381.86 M Stocks
Jan 1, 2021
435.83 M Stocks
Jan 1, 2022
443.00 M Stocks
Jan 1, 2023
449.28 M Stocks
Jan 1, 2024
448.21 M Stocks
Jan 1, 2025 (e)
448.21 M Stocks
Jan 1, 2026 (e)
448.21 M Stocks
Jan 1, 2027 (e)
448.21 M Stocks

Niox Group Dividend History

3 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.01GBP↑ 25.0%1×
May 15, 20250.01GBP↑ 25.0%1/1
20240.01GBP↓ 60.0%1×
20230.03GBP—1×

Niox Group dividend history and estimates

In 2025, Niox Group paid a dividend amounting to 0.01 GBP. Dividend means that Niox Group distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2023 (e)
0.03 GBP
0.00 GBP
0.00 GBP
Jan 1, 2024
0.01 GBP
0.00 GBP
0.00 GBP
Jan 1, 2025
0.01 GBP
0.00 GBP
0.00 GBP
Jan 1, 2026 (e)
0.00 GBP
0.02 GBP
0.00 GBP
Jan 1, 2027 (e)
0.00 GBP
0.02 GBP
0.00 GBP

Niox Group dividend payout ratio

In 2025, Niox Group had a payout ratio of 49.13%. The payout ratio indicates the percentage of the company's profits that Niox Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
124.75 %
Jan 1, 2021
124.75 %
Jan 1, 2022
124.75 %
Jan 1, 2023
117.92 %
Jan 1, 2024
131.58 %
Jan 1, 2025 (e)
49.13 %
Jan 1, 2026 (e)
42.15 %
Jan 1, 2027 (e)
45.10 %

Current Niox Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.20 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
0.84
Last Price
0.69
Currency
GBP
12M Return Potential
21.92 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Niox Group stock

52/100
36
Environment
66
Social
54
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy83
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions83
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees47
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Niox Group shareholder structure

% Name
16.82459%
Harwood Capital LLP
Harwood Capital LLP
15.81440%
AstraZeneca PLC
AstraZeneca PLC
10.50992%
Rathbones Investment Management Limited
Rathbones Investment Management Limited
5.90943%
Charles Stanley Group PLC
Charles Stanley Group PLC
4.92798%
Griffiths (Richard)
Griffiths (Richard)
3.16683%
Danske Bank Asset Management
Danske Bank Asset Management

Niox Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
78.2%
Float Shares
-
Shares Outstanding
-

Niox Group Executives and Management Board

7 members · avg. age 53 · 29 % women

JE

Mr. Jonathan Emms

Chief Executive Officer, Executive Director · since 2019

860,000.00 GBP

Management

SD

Ms. Sarah Duncan

Chief Financial Officer, Executive Director · since 2020

–

Board of Directors

IJ

Mr. Ian Johnson (71)

Non-Executive Chairman of the Board · since 2019

851,000.00 GBP
GW

Mr. Garry Watts

Senior Non-Executive Independent Director

74,000.00 GBP
SC

Ms. Sharon Curran (56)

Non-Executive Independent Director

70,000.00 GBP
NM

Mr. Nicholas Mills (34)

Non-Independent Non-Executive Director

47,000.00 GBP
RN

Mr. Robert Naylor (50)

Non-Executive Independent Director

34,000.00 GBP

Frequently asked questions about Niox Group

The business model of Circassia Group PLC revolves around the development, commercialization, and sale of innovative specialty pharmaceutical products. Circassia focuses on the treatment of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Through its advanced technology and expertise, Circassia aims to improve patient outcomes and enhance the quality of respiratory care. With a strong portfolio of products, the company is committed to enhancing treatment options and addressing unmet medical needs. Circassia Group PLC strives to make a significant impact on respiratory health globally.

Circassia Group PLC is primarily active in the healthcare and pharmaceutical industries. The company focuses on developing and commercializing innovative products for the treatment of respiratory diseases and allergies. Circassia aims to improve the lives of patients by addressing unmet medical needs through its expertise in immunology and respiratory science. With a strong portfolio of products, Circassia is dedicated to providing effective solutions and enhancing patient care in these critical industries.

The main competitors of Circassia Group PLC in the market include pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Teva Pharmaceuticals.

Circassia Group PLC is a pharmaceutical company specializing in the development and commercialization of innovative allergy and respiratory products. Established in 2006, Circassia has been dedicated to improving the lives of patients suffering from various respiratory conditions. With a strong emphasis on research and development, the company has successfully delivered breakthrough treatments using its proprietary technologies. Circassia's mission is to provide effective and safe solutions for respiratory diseases, including allergic rhinitis and asthma. With a focus on improving patients' quality of life, Circassia Group PLC continues to expand its portfolio and explore new opportunities in the field of respiratory medicine.

Some significant milestones achieved by Circassia Group PLC include the successful completion of Phase III clinical trials for its respiratory disease products, the establishment of strategic partnerships with leading pharmaceutical companies, and the launch of several innovative treatments in multiple markets. Circassia Group PLC has also been granted regulatory approvals for its products in key markets, further contributing to its growth and market presence. The company continues to invest in research and development to bring advanced therapies to patients, solidifying its position as a prominent player in the healthcare industry.

Circassia Group PLC is primarily present in the United Kingdom.

Circassia Group PLC represents core values of innovation, collaboration, and patient-centered care. With a strong corporate philosophy focused on improving the lives of patients, Circassia aims to develop and commercialize innovative medical solutions. By fostering collaborations with key partners, the company strives to accelerate research and bring cutting-edge therapies to address unmet medical needs. Circassia's commitment to patient-centered care ensures that their products are designed to provide optimal outcomes and enhance the quality of life for patients. Through its dedication to innovation, collaboration, and patient-focused solutions, Circassia Group PLC stands as a leading player in the healthcare industry.

Analysts currently set an average price target of 85.07 GBP for the Niox Group stock (median: 83.64 GBP), implying +24.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Niox Group Analyst Price Targets 2026

9 analysts currently rate the Niox Group stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Niox Group to generate revenue of 50.50 M GBP and earnings per share of 0.03 GBP.

Niox Group Analyst Price Targets 2026

Converted at the current exchange rate, the Niox Group share trades at 0.80 EUR (0.69 GBP).

The Niox Group share (NIOX.L) is listed on 5 stock exchanges, including: Frankfurt (82C.F), London (CIR.L), London (CIR.L), SIX (Zürich) (82C.SW).

The Circassia Group PLC is a biopharmaceutical company that specializes in the development and marketing of products for the treatment of respiratory diseases and allergies. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. The business activities of Circassia Group PLC are divided into two divisions: the respiratory division and the allergology division. In the respiratory division, the company develops therapies and medications for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. The allergology division focuses on the treatment of allergies, including hay fever and food allergies. One of Circassia's key innovations in the respiratory division is the NIOX system, which allows for non-invasive measurement of inflammation markers in the breath. This enables more precise determination of the severity of respiratory diseases such as asthma, improving treatment and disease control. The company also offers the Tudorza Pressair inhalation device for the treatment of COPD patients. In the allergology division, Circassia has developed a portfolio of immunotherapeutic treatments for a variety of allergies, including grass pollen, tree pollen, and house dust mites. The company has also partnered with Anergis to develop a therapy for food allergies. Circassia Group PLC's business strategy focuses on product and therapy innovation. The company invests heavily in research and development to develop new and more effective treatments for respiratory and allergy diseases. Circassia has a team of experienced scientists and clinicians who work closely together to ensure that the company's products meet the highest clinical standards. Circassia Group PLC is also expanding globally and has partnerships and distribution agreements with companies in Asia, Europe, and North America. The company has an international distribution network that ensures access to its products in key markets worldwide. The revenue of Circassia Group PLC primarily comes from the sale of products, including NIOX and Tudorza Pressair. The company has also entered into a number of licensing agreements that allow for the use of technologies and products in new markets and indications. Overall, Circassia Group PLC is a leading company in the development of products for the treatment of respiratory and allergy diseases. Through a combination of innovation and expansion strategy, the company has built a strong presence in key markets and is expected to continue to grow and expand.

The expected revenue of Niox Group is 50.50 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Niox Group is 14.87 M GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Niox Group is currently 20.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Niox Group stock.

The price-to-sales ratio (P/S) of Niox Group is currently 6.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Niox Group stock.

The Eulerpool Quality Score for Niox Group is 7/10.

The ISIN of Niox Group is GB00BJVD3B28. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Niox Group is A1XFBM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Niox Group is NIOX.L. The ticker symbol is used to trade Niox Group shares on the stock exchange.

Over the past 12 months, Niox Group paid a dividend of 0.01 GBP . This corresponds to a dividend yield of about 1.46 %. For the coming 12 months, Niox Group is expected to pay a dividend of 0.02 GBP.

The current dividend yield of Niox Group is 1.46 %.

Niox Group paid dividends every year for the past 3 years.

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 2.62 %.

Niox Group is assigned to the 'Health' sector.

To receive the latest dividend of Niox Group from amounting to 0.01 GBP, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Niox Group distributed 0.01 GBP as dividends.

The dividends of Niox Group are distributed in GBP.

All fundamentals and in-depth analysis of Niox Group

Our stock analysis for Niox Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Niox Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Niox Group Stock
Niox Group Revenue→
Niox Group Stock
Niox Group Net Income→
Niox Group Stock
Niox Group P/E→
Niox Group Stock
Niox Group P/S→
Niox Group Stock
Niox Group EBIT→
Niox Group Stock
Niox Group Dividend→
Niox Group Stock
Niox Group Directors Dealings→
Niox Group Stock
Niox Group Stocks→
Niox Group Stock
Niox Group Market capitalization→
Niox Group Stock
Niox Group Debt→
Niox Group Stock
Niox Group Liabilities→
Niox Group Stock
Niox Group Equity→
Niox Group Stock
Niox Group AAQS→
Niox Group Stock
Niox Group Employees→
Niox Group Stock
Niox Group ROE→
Niox Group Stock
Niox Group ROA→
Niox Group Stock
Niox Group ROCE→
Niox Group Stock
Niox Group News→
Niox Group Stock
Niox Group Analyst Price Targets→

Health Stocks

Nippon Care Supply CoNingbo Tianyi Medical Appliance CoNippon Chemiphar CoNingbo Menovo Pharmaceutical CoNippon Shinyaku CoNingbo David Medical Device CoNiproNihon KohdenNissan Medical IndustriesNightingale Health OyjNkartaNidhogg Resources Holding AB (publ)All Stocks A–Z →